As of June 14, 2025, Poniard Pharmaceuticals Inc (PARD) reports a ROA (Return on Assets) of -258.10%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Poniard Pharmaceuticals Inc's ROA (Return on Assets)
Over recent years, Poniard Pharmaceuticals Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2010-12-31 | -258.10% |
| 2009-12-31 | -87.17% |
| 2008-12-31 | -57.66% |
| 2007-12-31 | -31.18% |
| 2006-12-31 | -33.73% |
This slight downward trend highlights how Poniard Pharmaceuticals Inc manages its efficiency in using assets to generate earnings over time.
Comparing Poniard Pharmaceuticals Inc's ROA (Return on Assets) to Peers
To better understand Poniard Pharmaceuticals Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Poniard Pharmaceuticals Inc (PARD) | -258.10% |
| Gossamer Bio Inc (GOSS) | -17.93% |
| Xeno Transplants Corp (XENO) | -19.99% |
| Caladrius Biosciences Inc (CLBS) | -28.31% |
| Karuna Therapeutics Inc (KRTX) | -32.46% |
| Stromacel Inc (PROT) | -41.42% |
Compared to its competitors, Poniard Pharmaceuticals Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.